低剂量口服Vp-16治疗晚期胃癌18例近期疗效分析

Analysis of the Short Term Effect of Low Dose Oral Etoposide (Vp-16)For 18 Cases of Advanced Gastric Carcinoma.

用低剂量口服Ｖｐ－１６的ＥＬＦ（ＣＦ／５Ｆｕ、Ｖｐ－１６）方案治疗的均经病理证实的晚期胃癌１８例，结果ＣＲ１例，ＰＲ７例，总有效率（ＣＲ＋ＰＲ）４４．４％，至现在存活时间最长的为３４个月，最短的为２个月，中位生存期８．６个月。化疗主要毒副作用为消化道反应及骨髓抑制，但均不严重。对心、肝、肾功能无大影响。

18 cases of Advance Gastric Carcinoma were treated with combined modality predominated by low dose oral etoposide(Vp16).The results showed that respons rate was 44.4%(CR1,PR7).Up to now,the median survival term was 8.6 months,The adverse reaction of myclosuppression and gastrointestine symptoms resulted from the chemotherapy was mild to moderate.